Sublethal ciprofloxacin treatment leads to resistance via antioxidant systems in Proteus mirabilis

FEMS Microbiology Letters

Volumn 327, Issue 1, 2012, Pages 25-32

  Aiassa, Virginia ^a   Barnes, Ana I ^a   Smania, Andrea M ^a   Albesa, Inés ^a  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

Author keywords

Antioxidant systems; Ciprofloxacin; Proteus mirabilis; Resistance

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; ANTIOXIDANT; ASCORBIC ACID; CARBONYL CYANIDE CHLOROPHENYLHYDRAZONE; CARBONYL DERIVATIVE; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; GLUTATHIONE; MALONALDEHYDE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; CROSS RESISTANCE; FERRIC REDUCING ANTIOXIDANT POWER; GENE MUTATION; GENE SEQUENCE; GRYA GENE; GRYB GENE; IN VITRO STUDY; LIPID PEROXIDATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATION; OXIDATIVE STRESS; PARC GENE; PRIORITY JOURNAL; PROTEIN OXIDATION; PROTEUS MIRABILIS;

ANTI-BACTERIAL AGENTS; ANTIOXIDANTS; BACTERIAL PROTEINS; CIPROFLOXACIN; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; LIPID PEROXIDATION; MOLECULAR SEQUENCE DATA; OXIDATIVE STRESS; PROTEUS MIRABILIS;

COWBONE RIDGE VIRUS; PROTEUS MIRABILIS;

EID: 84855505745     PISSN: 03781097     EISSN: 15746968     Source Type: Journal    
DOI: 10.1111/j.1574-6968.2011.02453.x     Document Type: Article

References (35)

1. Aiassa V, Barnes AI & Albesa I (2007) Action of ciprofloxacin on planktonic bacteria and biofilm of Proteus mirabilis. Biofilms 3: 11-17.
2. Aiassa V, Barnes AI & Albesa I (2010) Resistance to ciprofloxacin by enhancement of antioxidant defenses in biofilm and planktonic Proteus mirabilis. Biochem Biophys Res Commun 393: 84-88.
3. Albesa I, Becerra MC, Battán PC & Páez PL (2004) Oxidative stress involved in the antibacterial action of different antibiotics. Biochem Biophys Res Commun 317: 605-609.
4. Becerra MC & Albesa I (2002) Oxidative stress induced by ciprofloxacin in Staphylococcus aureus. Biochem Biophys Res Commun 297: 1003-1007.
5. Benzie IF & Strain JJ (1996) The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem 239: 70-76.
6. Benzie IF & Strain JJ (1999) Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. Methods Enzymol 299: 15-27.
7. Chen PR, Brugarolas P & He C (2011) Redox signaling in human pathogens. Antioxid Redox Signal 14: 1107-1118.
8. Di Bernardini R, Rai DK, Bolton D, Kerry J, O'Neill E, Mullen AM, Harnedy P & Hayes M (2011) Isolation, purification and characterization of antioxidant peptidic fractions from a bovine liver sarcoplasmic protein thermolysin hydrolyzate. Peptides 32: 388-400.
9. Dwyer DJ, Kohanski MA & Collins JJ (2009) Role of reactive oxygen species in antibiotic action and resistance. Curr Opin Microbiol 12: 482-489.
10. Giraud E, Brisabois A, Martel JL & Chaslus-Dancla E (1999) Comparative studies of mutations in animal isolates and experimental in-vitro and in-vivo mutants of Salmonella spp. suggest a counter selection of highly fluoroquinolone-resistant strains in the field. Antimicrob Agents Chemother 43: 2131-2137.
11. Goswami M, Mangoli SH & Jawali N (2006) Involvement of reactive oxygen species in the action of ciprofloxacin against Escherichia coli. Antimicrob Agents Chemother 50: 949-954.
12. Huang D, Ou B & Prior RL (2005) The chemistry behind antioxidant capacity assays. J Agric Food Chem 23: 1841-1856.
13. Kern WV, Oethinger M, Jellen-Ritter AS & Levy SB (2000) Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 44: 814-820.
14. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA & Collins JJ (2007) A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130: 797-810.
15. Kohanski MA, De Pristo MA & Collins JJ (2010) Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. Mol Cell 37: 311-320.
16. Koziol S, Zagulski M, Bilinski T & Bartosz G (2005) Antioxidants protect the yeast Saccharomyces cerevisiae against hypertonic stress. Free Radic Res 39: 365-371.
17. Krisko A & Radman M (2010) Protein damage and death by radiation in Escherichia coli and Deinococcus radiodurans. P Natl Acad Sci USA 107: 14373-14377.
18. Litescu SC, Eremia S & Radu GL (2011) Methods for the determination of antioxidant capacity in food and raw materials. Adv Exp Med Biol 698: 241-249.
19. Magalhães LM, Segundo MA, Reis S & Lima JL (2008) Methodological aspects about in vitro evaluation of antioxidant properties. Anal Chim Acta 613: 1-19.
20. Maneewannakul K & Levy SB (1996) Identification of mar mutants among quinolone-resistant clinical isolates of Escherichia coli. Antimicrob Agents Chemother 40: 1695-1698.
21. Miller P & Sulavik MC (1996) Overlaps and parallels in the regulation of intrinsic multiple-antibiotic resistance in Escherichia coli. Mol Microbiol 21: 441-448.
22. Nilsson J, Pillai D, Onning G, Persson C, Nilsson A & Akesson B (2005) Comparison of the 2, 2′-azinobis-3-ethylbenzotiazo-line-6-sulfonic acid (ABTS) and ferric reducing anti-oxidant power (FRAP) methods to assess the total antioxidant capacity in extracts of fruit and vegetables. Mol Nutr Food Res 49: 239-246.
23. Oethinger M, Podglajen I, Kern WV & Levy SB (1998) Overexpression of the marA or soxS regulatory gene in clinical topoisomerase mutants of Escherichia coli. Antimicrob Agents Chemother 42: 2089-2094.
24. Páez PL, Becerra MC & Albesa I (2010) Effect of the association of reduced glutathione and ciprofloxacin on the antimicrobial activity in Staphylococcus aureus. FEMS Microbiol Lett 303: 101-105.
25. Piddock L (1999) Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs 58: 1-8.
26. Piechota A & Goraca A (2009) [The comparison of alpha-lipoic acid, melatonin, vitamin C and trolox effectiveness in decreasing DNA stand brakes and increasing plasma antioxidant power]. Pol Merkur Lekarski 27: 19-21.
27. Ruiz J (2003) Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother 51: 1109-1117.
28. Saito R, Sato K, Kumita W, Inami N, Nishiyama H, Okamura N, Moriya1 K & Koike K (2006) Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis. J Antimicrob Chemother 58: 673-677.
29. Schlesier K, Harwat M, Böhm V & Bitsch R (2002) Assessment of antioxidant activity by using different in vitro methods. Free Radic Res 36: 177-187.
30. Stauffer CE (1975) A linear standard curve for the Folin Lowry determination of protein. Anal Biochem 69: 646-648.
31. Tattevin P, Basuino L & Chambers HF (2009) Subinhibitory fluoroquinolone exposure selects for reduced beta-lactam susceptibility in methicillin-resistant Staphylococcus aureus and alterations in the SOS-mediated response. Res Microbiol 160: 187-192.
32. Thaipong K, Boonprakob U, Crosby K, Cisneros-Zevallos L & Byrne DH (2006) Comparison of ABTS, DPPH, FRAP, and ORAC assays for estimating antioxidant activity from guava fruit extracts. J Food Compost Anal 19: 669-675.
33. Weigel LM, Anderson GJ & Tenover FC (2002) DNA gyrase and topoisomerase IV mutations associated with fluoroquinolone resistance in Proteus mirabilis. Antimicrob Agents Chemother 46: 2582-2587.
34. Wick LM & Egli T (2004) Molecular components of physiological stress responses in Escherichia coli. Adv Biochem Eng Biotechnol 89: 1-45.
35. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillère-Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers P, Drüeke T & Descamps-Latscha B (1998) Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161: 2524-2532.